Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials

Schizophrenia Research

Volumn 111, Issue 1-3, 2009, Pages 39-45

  Citrome, Leslie ^a   Yang, Ruoyong ^b   Glue, Paul ^c   Karayal, Onur N ^b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

All cause discontinuation; Effectiveness; Randomized clinical trial; Schizophrenia; Ziprasidone

Indexed keywords

PLACEBO; ZIPRASIDONE;

ACUTE DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 67349200377     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.03.009     Document Type: Article

References (25)

1. Arato M., O'Connor R., Meltzer H.Y., and ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/d in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Psychopharmacol. 17 5 (2002) 207-215
2. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr. Scand. 117 6 (2008) 412-419
3. Citrome L., and Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev. Neurother. 8 7 (2008) 1079-1091
4. Citrome L., and Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv. Rev. Psychiatry 10 5 (2002) 280-291
5. Citrome L., Jaffe A., and Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr. Serv. 58 1 (2007) 11
6. Citrome L., Jaffe A., and Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J. Clin. Psychopharmacol. 25 4 (2005) 388-391
7. Citrome, L., Jaffe, A., Levine, J., in press. How dosing of ziprasidone in a state hospital system differs from product labeling. J. Clin. Psychiatry.
8. Citrome L., Reist C., Palmer L., Montejano L., Lenhart G., Cuffel B., Harnett J., and Sanders K.N. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr. Res. 108 1-3 (2009) 238-244
9. Daniel D.G., Zimbroff D.L., Potkin S.G., Reeves K.R., Harrigan E.P., and Lakshminarayanan M. Ziprasidone 80 mg/d and 160 mg/d in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20 5 (1999) 491-505
10. Davis J.M., and Chen N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 24 2 (2004) 192-208
11. Gandelman K., Alderman J.A., Glue P., Lombardo I., LaBadie R.R., Versavel M., and Preskorn S.H. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, cross-over trial. J. Clin. Psychiatry 70 1 (2009) 58-62
12. Goff D.C., Posever T., Herz L., Simmons J., Kletti N., Lapierre K., Wilner K.D., Law C.G., and Ko G.N. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J. Clin. Psychopharmacol. 18 4 (1998) 296-304
13. Hamelin B.A., Allard S., Laplante L., Miceli J., Wilner K.D., Tremblay J., and LeBel M. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 18 1 (1998) 9-15
14. Joyce A.T., Harrison D.J., Loebel A.D., Carter C.T., and Ollendorf D.A. Effect of initial ziprasidone dose on length of therapy in schizophrenia. Schizophr. Res. 83 2-3 (2006) 285-292
15. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E., and EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 9618 (2008) 1085-1097
16. Keck Jr. P., Buffenstein A., Ferguson J., Feighner J., Jaffe W., Harrigan E.P., and Morrissey M.R. Ziprasidone 40 mg and 120 mg/d in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 140 2 (1998) 173-184
17. Kinon B.J., Lipkovich I., Edwards S.B., Adams D.H., Ascher-Svanum H., and Siris S.G. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J. Clin. Psychopharmacol. 26 2 (2006) 157-162
18. Kraemer H.C., and Kupfer D.J. Size of treatment effects and their importance to clinical research and practice. Biol. Psychiatry 59 11 (2005) 990-996
19. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
20. Mamo D., Kapur S., Shammi C.M., Papatheodorou G., Mann S., Therrien F., and Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 161 5 (2004) 818-825
21. Miceli J.J., Glue P., Alderman J., and Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol. Bull. 40 3 (2007) 58-68
22. Mullins C.D., Shaya F.T., Zito J.M., Obeidat N., Naradzay J., and Harrison D.J. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. Schizophr. Res. 83 2-3 (2006) 277-284
23. Pfizer. Geodon: US Package Insert for Geodon (ziprasidone HCl) and Geodon (ziprasidone mesylate) for Injection, LAB-0272-2.0 (2007). http://www.pfizer.com/files/products/uspi_geodon.pdf Available at: http://www.pfizer.com/files/products/uspi_geodon.pdf. Accessed 2008 June 2
24. Stahl S.M., and Shayegan D.K. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J. Clin. Psychiatry 64 Suppl 19 (2003) 6-12
25. Stimmel G.L., Gutierrez M.A., and Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clinical Therapeutics 24 1 (2002) 21-37